Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China
· Delayed Price · Currency is CNY 21.56
+0.65 (3.11%)
May 16, 2025, 3:00 PM CST
Aurisco Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | 392.03 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 | Upgrade
|
| Depreciation & Amortization | 87.01 | 87.01 | 79.11 | 69.24 | 54.77 | 32.02 | Upgrade
|
| Other Amortization | 3.2 | 3.2 | 2.54 | 1.55 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.41 | 0.41 | 1.53 | 1.5 | 0.4 | 0.26 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.17 | 0.17 | - | - | - | 0.05 | Upgrade
|
| Loss (Gain) From Sale of Investments | -5.62 | -5.62 | -31.72 | 1.19 | -0.68 | -2.36 | Upgrade
|
| Provision & Write-off of Bad Debts | 3.55 | 3.55 | 4.18 | 4.19 | -0.09 | 0.74 | Upgrade
|
| Other Operating Activities | -80.55 | 20.4 | 6 | 3.89 | 2.33 | 8.6 | Upgrade
|
| Change in Accounts Receivable | -107.13 | -107.13 | -98.18 | -84.83 | 11.29 | -20.72 | Upgrade
|
| Change in Inventory | -201.43 | -201.43 | -72.52 | -125.97 | -89.01 | 1.83 | Upgrade
|
| Change in Accounts Payable | 161.15 | 161.15 | 174.55 | 70.56 | 55.41 | 30.65 | Upgrade
|
| Change in Other Net Operating Assets | 17.59 | 17.59 | 34.28 | 17.98 | 1 | 2.53 | Upgrade
|
| Operating Cash Flow | 268.68 | 332.41 | 385.61 | 166.41 | 201.57 | 214.48 | Upgrade
|
| Operating Cash Flow Growth | -32.01% | -13.80% | 131.72% | -17.44% | -6.02% | 19.22% | Upgrade
|
| Capital Expenditures | -507.94 | -540.28 | -305.48 | -216.23 | -250.61 | -158.8 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.39 | 1.28 | 0.52 | 0.63 | 0.6 | 0.82 | Upgrade
|
| Divestitures | - | - | 61.09 | - | - | - | Upgrade
|
| Investment in Securities | -148.88 | -191.34 | -121.44 | -41.44 | -15 | - | Upgrade
|
| Other Investing Activities | 5.48 | 3.56 | 0.03 | 0.25 | 2.68 | 0.97 | Upgrade
|
| Investing Cash Flow | -649.95 | -726.77 | -365.27 | -256.79 | -262.34 | -157.01 | Upgrade
|
| Long-Term Debt Issued | - | 986.04 | 135.79 | 37.12 | - | - | Upgrade
|
| Total Debt Issued | 914.66 | 986.04 | 135.79 | 37.12 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -153.64 | -71.87 | -5.94 | -4.37 | - | Upgrade
|
| Total Debt Repaid | -96.06 | -153.64 | -71.87 | -5.94 | -4.37 | - | Upgrade
|
| Net Debt Issued (Repaid) | 818.6 | 832.4 | 63.92 | 31.18 | -4.37 | - | Upgrade
|
| Issuance of Common Stock | - | - | - | 57.15 | - | 312.28 | Upgrade
|
| Common Dividends Paid | -95.85 | -94.82 | -67 | -52.34 | -48.12 | -36 | Upgrade
|
| Other Financing Activities | -17.73 | -3.22 | 52.1 | -50.9 | - | -29.34 | Upgrade
|
| Financing Cash Flow | 705.02 | 734.37 | 49.02 | -14.91 | -52.49 | 246.94 | Upgrade
|
| Foreign Exchange Rate Adjustments | 12.19 | 14.02 | 6.11 | 3.5 | -3.82 | -6.29 | Upgrade
|
| Net Cash Flow | 335.95 | 354.02 | 75.47 | -101.79 | -117.08 | 298.12 | Upgrade
|
| Free Cash Flow | -239.26 | -207.87 | 80.13 | -49.82 | -49.04 | 55.68 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | -48.17% | Upgrade
|
| Free Cash Flow Margin | -15.52% | -14.09% | 6.35% | -4.94% | -6.11% | 7.72% | Upgrade
|
| Free Cash Flow Per Share | -0.60 | -0.52 | 0.20 | -0.12 | -0.12 | 0.15 | Upgrade
|
| Cash Income Tax Paid | - | -12.74 | -18.15 | -35.73 | -27.6 | -9.63 | Upgrade
|
| Levered Free Cash Flow | -403.17 | -303.79 | 36.02 | -102.36 | -116.14 | 4.25 | Upgrade
|
| Unlevered Free Cash Flow | -388.58 | -293.93 | 37.73 | -101.73 | -115.74 | 4.25 | Upgrade
|
| Change in Net Working Capital | 267.14 | 106.79 | -46.31 | 104.5 | 34.12 | -11.11 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.